Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis.

被引：0
|
作者：
van de Putte, BA
Rau, R
Breedveld, FC
Kalden, JR
Malaise, MG
Schattenkirchner, M
Emery, P
Burmester, GR
Zeidler, H
Moutsopoulos, HH
Compagnone, D
Kempeni, J
Kupper, H
机构：
来源：
ARTHRITIS AND RHEUMATISM | 1999年 / 42卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1977
引用
收藏
页码：S400 / S400
页数：1
相关论文
共 50 条
  • [1] One year efficacy results of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis.
    van de Putte, LBA
    Rau, R
    Breedveld, FC
    Kalden, JR
    Malaise, MG
    Schattenkirchner, M
    Emery, P
    Burmester, GR
    Zeidler, H
    Dressler, R
    Compagnone, D
    Kempeni, J
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S269 - S269
  • [2] Generation of fully human anti-TNF antibody D2E7
    Salfield, J
    Kaymakçalan, J
    Tracey, D
    Roberts, A
    Kamen, R
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S57 - S57
  • [3] Long-term use of the fully human anti-TNF antibody D2E7 in combination with methotrexate in active rheumatoid arthritis.
    Schattenkirchner, M
    Wastlhuber, J
    Rau, R
    Herborn, G
    Kroot, EJ
    van Riel, PLCM
    van de Putte, LBA
    Ailaart, CF
    Breedveld, FC
    Fenner, H
    Theophil, E
    Kempeni, J
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S228 - S228
  • [4] A single dose placebo controlled phase 1 study of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis.
    van de Putte, LBA
    van Riel, PLCM
    den Broeder, A
    Sander, O
    Rau, R
    Binder, C
    Krüger, K
    Schattenkircher, M
    Fenner, H
    Salfeld, J
    Bankmann, Y
    Kupper, H
    Kempeni, J
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S57 - S57
  • [5] Improvement in health utility among rheumatoid arthritis (RA) patients treated with adalimumab (D2E7),a fully human anti-TNF monoclonal antibody
    van de Putte, L
    Boggs, R
    Sengupta, N
    Dietz, B
    Bergemann, R
    Rosery, H
    Kupper, H
    VALUE IN HEALTH, 2002, 5 (06) : 461 - 461
  • [6] Long-term efficacy and tolerability of multiple i.v. doses of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis.
    Rau, R
    Sander, O
    den Broeder, A
    van Riel, PLCM
    van der Putte, L
    Krüger, K
    Schattenkircher, M
    Fenner, H
    Lassmann, A
    Kupper, H
    Kempeni, J
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S55 - S55
  • [7] Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7
    Kempeni, J
    ANNALS OF THE RHEUMATIC DISEASES, 1999, 58 : 70 - 72
  • [8] Long-term treatment with the fully human anti-TNF-antibody D2E7 slows radio-graphic disease progression in rheumatoid arthritis.
    Rau, R
    Herborn, G
    Sander, O
    van de Putte, LBA
    van Riel, PLC
    den Broeder, A
    Schattenkirchner, M
    Wastlhuber, J
    Rihl, M
    Fenner, H
    Kempeni, J
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S400 - S400
  • [9] Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis -: Results of a phase I study
    Schattenkirchner, M
    Krüger, K
    Sander, O
    Rau, R
    Kroot, EJ
    van Riel, PLCM
    van de Putte, L
    Fenner, H
    Kempeni, J
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S57 - S57
  • [10] Pharmacokinetics of adalimumab (D2E7), a fully human anti-TNF-α monoclonal antibody, following a single intravenous injection in rheumatoid arthritis patients treated with methotrexate
    Velagapudi, RB
    Noertershauser, P
    Bankmann, Y
    Granneman, RG
    Awni, W
    Chartash, E
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S133 - S133
12345